Breast Cancer Drugs Market by Drug Type (Hormone Therapy, Chemotherapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020–2029

  • TBI633835
  • November 29, 2020
  • No Countries Found
  • 132 pages
  • SAC Insights


The report covers a forecast and an analysis for the breast cancer drugs market on a global and regional level. The study provides historical data from 2015 to 2020 along with forecast from 2021 to 2029 based on revenue (USD Billion). The study includes drivers and restraints for the breast cancer drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the breast cancer drugs market on a global and regional level. In order to give the users of this report a comprehensive view of the breast cancer drugs market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness. The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. The study provides a decisive view of the breast cancer drugs market by segmenting the market based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs. Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies. Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc. The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. Some key players of the global breast cancer drugs market include AbbVie, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Biocon, Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc. In October 2020, Novartis Europharm Limited received marketing authorization valid throughout the European Union for Piqray (active substance alpelisib) which is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or has spread to other parts of the body. Piqray can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not have large quantities of another receptor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called PIK3CA. Piqray is used with the medicine fulvestrant. The active substance in Piqray, alpelisib, works by blocking the activity of the abnormal PI3K, thereby reducing the growth and spread of the cancer. Piqray used with fulvestrant increased the time before the disease got worse in patients with HR-positive and HER2-negative breast cancer that is advanced or has spread. Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. The cost for Piqray oral tablet (200 mg-50 mg) is around USD$17,000 for a supply of 60 tablets. Piqray is available as a brand name drug only, a generic version is not yet available In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers. Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion. The cost for Herceptin intravenous powder in the US for injection of 150 mg is around $1,500 for a supply of 1 powder for injection. UK trastuzumab market is size is close to US$96.2 Million in 2020.

This report segments the global breast cancer drugs market into:

Global Breast Cancer Drugs Market: By Drug Type

Chemotherapy Drugs

  • Anthracyclines
  • Doxorubicin
  • Epirubicin
  • Paclitaxel
  • Docetaxel
  • Fluorouracil
  • Capecitabine
  • Gemcitabine (Gemcitabine Injection (the generic equivalent of Eli Lillys, Gemzar®), available in 200mg/5.26mL, 1G/26.3mL and 2G/52.6mL; has an approximate market size of $25M, annually.)
Alkylating Agents
  • Epothilones

Hormone Therapy Drugs

  • Selective Estrogen-Receptor Modulators (SERMs)
  • Tamoxifen
  • Raloxifene
  • Toremifene

Aromatase Inhibitors

  • Letrozole
  • Anastrozole
  • Megestrol

Other Hormonal Therapies

  • Goserelin acetate
  • Fulvestrant
  • Fluoxymesterone

Targeted Therapy Drugs

  • Monoclonal Antibodies (mAbs)
  • Bevacizumab
  • Trastuzumab
  • Other mAbs

Tyrosine kinase inhibitors

Other Therapeutic Drugs

Global Breast Cancer Drugs Market: By Region

    • North America
    • Europe
    • Asia Pacific
  • Latin America
  • Middle East and Africa

Table of Contents
                         Request Table Of Content
                         Click To Request Sample

	Chapter 1. Introduction
		1.1. Report description and scope
		1.2. Research scope
		1.3. Research methodology
			1.3.1. Market research process
			1.3.2. Market research methodology
	Chapter 2. Executive Summary
		2.1. Global Breast Cancer Drugs Market Revenue, 2016-2025 (USD Billion)
		2.2. Global Breast Cancer Drugs Market: Snapshot
| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form